Professional Documents
Culture Documents
月刊 1970 年 11 月创刊
2018 年 12 月 10 日出版
liposomes
·专论与综述·
polymeric nanocarriers
solid lipid nanoparticles
1635 质量源于设计(QbD)理念在脂质体开发中的应用························································
inhalable nanocarrier-based
drug delivery system for lung
materials
lipid nanocarriers nanostructured lipid carriers
····························································王笑笑,王君吉,赵
cancer therapy 源,何 军*,陆伟根
lipid nanocapsules
DOI:10.16522/j.cnki.cjph.2018.12.001 hybrid lipid-polymer
nanoparticles
LHRH receptors
粒径
知识空间
关键物料比例 folate receptors
多分散性
处方因素 设计空间
actively-targeted inhalable cancer cell surface
transferrin receptors
nanoparticles
包封率 targeting
安全性
epidermal growth factor receptors
有效性 ζ电位
工艺因素 tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)
确定QTPP 确定CQAs 确定CPPs 建立设计空间
tumor endothelium targeting iRGD α v integrins tumor-
homing peptide
1644 肺部吸入纳米药物递送系统治疗肺癌的研究进展·········金玉琼, 裘 渊, 曹 坤, 贺 芬*
DOI:10.16522/j.cnki.cjph.2018.12.002
particle size
knowledge space
ratio of critical materials 脂质体
polydispersity
聚合物纳米粒 design space
drug formulation factors 固体脂质纳米粒
entrapment
safety 材料 efficiency
肺部吸入纳米药物输送系统
efficacy 脂质纳米粒 纳米结构脂质载体
治疗肺癌 ζ potential
process factors
脂质纳米囊
脂质聚合物杂化纳米粒
identifying QTPP defining CQAs screening CPPs defining design space
LHRH 受体
construction 叶酸受体
high doxorubicin strain plasmids
肿瘤细胞表面靶向
主动靶向吸入纳米粒
key genes 转铁蛋白受体
conjugation
表皮生长因子受体
ΔdnmV genome attB site 超声时间
超声振幅
肿瘤坏死因子相关凋亡
超声强度诱导配体(TRAIL)
孵化 site-specific scale-up in
translation integration in
肿瘤血管内皮靶向
α v 整合素肿瘤归巢肽
genome 聚合时间
fermenter聚合温度 (iRGD)
聚合
聚合转速
O OH
O
水合时间
OH C H 2 OH
·研究论文· 水合
O biosynthetic pathway
OH 水合温度
挥发时间
HO
HO
of epirubicin OH O OH O
OH
OH
H3 C
HO
O 挥发温度
溶剂挥发
1653 产表阿霉素重组波赛链霉菌的构建·······································王晓茹,田晓蓉,陈少欣
starch or its
hydrolysis products
epirubicin
5 L fermenter * H2 N 挥发转速
加热时间
DOI:10.16522/j.cnki.cjph.2018.12.003
加热 加热温度
包载体积
阿霉素高产菌株 质粒构建
包载
关键基因
接合转移
LHRH attB整合位点
Drug dnmV点突变 基因组
基因组位点
翻译 特异性整合 扩大
DOTAP 培养
O OH
O
OH C H2 OH
siRNA OH
O
表阿霉素生物合成途径
HO
HO
DSPE-PEG OH O OH O
OH
H3 C O
OH HO
H2 N
淀粉及其水解产物
抗癌药、siRNA和靶向肽联合给药NLC的示意图 发酵罐
表阿霉素
Organ Distribution of NLC Distribution of NLC in Lungs Distribution of Tumor Targeted
LHRH-NLC in Lungs
Light Fluorescence
Tumor
Tissue
1% 4% 0% Lung
9% 0% Tumor
Lungs
8% Light Tissue
Spleen 13%
23%
Kidney Non-Tumor
59% Heart 83% Tissue
Non-Tumor
Dexrabeprazole Sodium
This optimized process has mild reaction conditions and simple operation, and it has been
tested in pilot scale with a totle yield of 83.0%, a purity of 99.9%, and a chiral purity of 99.9%.
1662 右旋雷贝拉唑钠的合成工艺优化··················吴素珍,鲍广龙,张乃华,陈成富,张贵民*
DOI:10.16522/j.cnki.cjph.2018.12.004
CH 3 CH 3 N CH 3
O O O O HS O O O O
O O O CH3
H CH 3 SOCl2 CH
H3
N H
CH 3
HCl H
CH3 N
SOCl2/CH3OH OHCl
O CHO NH HCl
OH DCM
OH Cl NaOH, H 2O / 丙酮 S
N NH2 N NH 2 HCl CH 3CN / i-PrOH N O
N
N N H
H H NH
O
CH 3 CH 3
O O O O
CH NaOH (a.q) CH 3
L-DET, Ti(O iPr) 4 , DIPEA CH3 3 CH3O
O N N
O O O ClS CH3CN O N S
过氧化氢二异丙苯 , 甲苯
Cl NH N HN
Cl CH3NH 2 N
N O H N Na
Et 3N, DCM O
EtOH
O 右旋雷贝拉唑钠
O
NH NH
O O
改进后的工艺反应条件温和、操作简便,总收率tadalafil
83.0%, 纯度 99.9%, 手性纯度 99.9%, 已经过中试验证。
The improved process has mild reaction conditions and simple operation, the purity of
the product is 99.9% with a total yield of 79%, and it has been produced in kilogram scale.
1666 公斤级他达拉非的合成······························杨传伟,刘 杰,刘文涛,李新志,吴世德*
DOI:10.16522/j.cnki.cjph.2018.12.005
O O
O O O CH3
H H H
SOCl2/CH3OH CH3 O CHO NH HCl
OH O
NH2 NH 2 HCl CH 3CN / i-PrOH O
N N CH3 NH CH3 N
H HO O O O
O HS 4
CH3 SOCl2 CH3 N
HCl H
HCl
OH DCM Cl NaOH, H 2O / 丙酮
CH3 N CHN3
O O O Cl O N
Cl
Cl H 2 盐酸盐 CH3NH 2 H 3
Two-phase
N O solvent (toluene/H2 O) was used to increase
N the
Et 3N, DCM O
total yield to about 80%,EtOH
and reduce the content of dimer impurity.
O O CH 3
NH NH O O O
O F OHO OO
NL-DET,F iPr) , DIPEA, 甲苯 N CH 3 NaOH (a.q)
Ti(O 4 toluene / H O
1) KOH,
NH2OH·HCl, Et3N 他达拉非 2 O FN
HN H 3C 2) HCl
CH S CH 3CN
EtOH/H2O HN
F
O OH N N F
3
HN HCl N
HCl 改进后的工艺反应条件温和、操作简便,产品纯度 99.9%,总收率 79%,已实现公斤级生产。 H
H 3C CH3 intermediate of risperidone
The yield was increased to 97% by 6
prolonging the reaction time to 12 h.
1670 6-氟-3-(4-哌啶基)-1,2-苯并异 唑盐酸盐合成工艺改进····黄文锋,张 剑,胡佳兴,余文龙*
DOI:10.16522/j.cnki.cjph.2018.12.006
O F OH O
N F N
NH2OH·HCl, Et3N 1) KOH, toluene / H 2O F
HN EtOH/H2O 2) HCl
F HN HN HCl
F
HCl
利培酮关键中间体 O
O O
H H
延长反应时间至12 h,收率提高至 97%。 SOCl2/CH3OH CH3 O CHO
OH O
NH2 60 ~ 65 ℃, 2 h NH 2 HCl CH 3CN / i-PrOH
N 94.5% N 80 ~ 85 ℃, 10 h
H H
98.5%
2 3
CH3
O O O Cl
Cl H
Cl CH3NH 2
N O
Et3N, DCM 95% EtOH
-5 ~ 5 ℃, 30 min O 50 ~ 55 ℃, 3 h
图1 O F OH 96.97% NH
N
O
O
87.2%
N F
NH2OH·HCl, Et3N 1) KOH, 甲苯 / H 2O
5 F
HN EtOH/H2O 2) HCl
F HN HN HCl
F
HCl
3 1
Sodium bicarbonate was used instead of diisopropylamine in
acetone at room temperature to give the product with a total yield of 64.2%.
用硼烷代替四氢铝锂进行还原反应,安全高效。 OH
O
OH C N Cl
O Cl (R)-carbonyl reductase 3
O O H 3C O Cl N
CH3 OH 1) Cl O
1) (COCl)2 BH 3 O CH3 , NaHCO3,丙酮F O Boc
OH O F CH3 CH3 O
O N
N N H 3C of
2) t-BuOK H Boc O
NAD+ intermediate nepirolol
Cl CH 3
N Cl N NHMe NADH
2) N
3) 甲胺 6 H 3C OH , EDCI, DMAP
硫酸艾沙康唑鎓关键中间体
gluconic acid glucose
glucose dehydrogenase
用碳酸氢钠代替二异丙胺在丙酮中反应,反应完全,总收率 64.2%。
The key intermediate of nepirolol was synthesized in the presence of glucose dehydrogenase coupled
with (R)-carbonyl reductase, with a yield of 91%, a purity of 98.3%, and a chiral HPLC purity of 99.6%.
1677 酶催化制备(R)-2-氯-1-[(R)-6-氟苯并二氢吡喃-2-基]-1-乙醇········································
····························································谷绪顶,王福军*,蒲 通,宋庆宝,刘玉坤
DOI:10.16522/j.cnki.cjph.2018.12.008
OH
O
O O O O HCl
3C O H 3C
O Cl (R)-羰基还原酶 CH3 H 3C CH 3
OH (COCl)2 Cl
t-BuOK O CH3 NH2 O CH 3
F
F
N Cl DCM N Cl THF N Cl
奈必洛尔关键中间体 N NHMe
NADH NAD+
2 3 4 5
葡萄糖酸 葡萄糖 H3C Cl
葡萄糖脱氢酶 Cl CH3
O Cl Boc O O O
7 N 8
BH3 OH Cl O CH3 O O H3C OH
利用葡萄糖脱氢酶耦合(R)-羰基还原酶催化制备奈必洛尔 N N
CH 3 H 3C
THF N N NaHCO91%,手性
关键中间体,纯度98.3%,收率 3 , 丙酮
N
HPLC 纯度 N
99.6%。 EDCI / DMAP
H CH 3 H 3C O
N
OH
6 Boc O
1
1684 微针辅助透皮贴片药物经皮渗透的促透效果考察························································
····························································夏 旭,高文彦,刘筱雅,沈 晨,叶金翠*
DOI:10.16522/j.cnki.cjph.2018.12.009
体内 药-时曲线下面积
达峰时间
O
最大血药浓度
药代动力学 OH
O Cl (R)- 羰基还原酶 O Cl
微针辅助处理皮肤F F
(R)-CLK NADH NAD+ (R,R)-CLA
不预处理皮肤
盐酸雷莫司琼贴片 葡萄糖酸 离体 稳态渗透速率
葡萄糖
48 h累积渗透量
葡萄糖脱氢酶
时滞
皮肤渗透
in vivo AUC0-- t
tmax
cmax
pharmacokinetics
nt
ata
药物含量无显著差异,
ern
测定灭菌与非灭菌
环氧乙烷气体不会对
sup
20
微针中的药物含量
微针中的药物产生影
15 响。
c/ng .ml - 1
10
1695 枸橼酸莫沙必利缓释片在Beagle犬体内的药动学························································
····························································喻明洁,向荣风,戴 青,熊丽蓉,陈勇川*
DOI:10.16522/j.cnki.cjph.2018.12.011 There was no significant
difference between sterile
determination of insulin microneedles and non-sterile
普通片(15 mg) lispro content in microneedles, meaning
microneedles ethylene oxide would not
have血浆influence on drug
缓释片(15 mg) content in microneedles.
莫沙必利 比格犬
液
efficiency of
上清
phase
20 transition incubate microneedle observed in 14 days.
microneedle patch sterilization
patches in ethylene
oxide atmosphere
15
c/ng .ml - 1
10
×10 3
5 COOH 1.4
H2N HOOC CH 3
O 1.2 Br CH
GC -MS/MS 1
3
N O
N 0 2O O4 6 8 CH 3 10 12 0.8
N P t/h O 0.6
N O O 普通片;O 缓释片 CH3 0.4
安捷伦液质联用仪
0.2
mAU
CH 3 O O 012 1
CH 3
10-1 0 1 2 3 4 5 6
1701 富马酸替诺福韦二吡呋酯中基因毒性杂质溴乙烷的GC-MS/MS法测定·····························
tenofovir disoproxil fumarate
8
6
t/min
genotoxic impurity detection
··········································································叶晓霞,吴静雯,乐
4
2
健,杨永健*
20
DOI:10.16522/j.cnki.cjph.2018.12.012 0
-2 ×10
×10-43 6
COOH a
HOOC 1.4 5.9
15 H2N CH 3 0 2.5 5 7.5
Br CH10 12.5 15 17.5 20
O 1.2 3
5.8
GC -MS/MS t/min
N O 1 5.7
N O O CH 3 mAU
0.8 1
-1
P O 12 5.6
c/ng .ml
10 N 0.610
N O O 5.5
O CH3 0.4 8
5.4
0.2 6
CH 3 O
5 O CH 3 04 5.3
2 5.2
0-1 0 1 2 3 4 5 6
富马酸替诺福韦二吡呋酯 -2 t/min 5.1
-4 基因毒性杂质检测 5
0 2 4 6 8 10 12 0 2.5 5 7.5 10 12.5 15 4.9
17.5 20
t/h t/min 4.8
普通片; 缓释片 0.2 0.
×103
2.8
a
2.6
2.4
2.2
2
1.8
1.6
in
p
1705 安神补心制剂的微生物限度检查及微生物的鉴定························································
····························································李 芳,冯 震,刘冬玲,刘 浩,杨美成*
DOI:10.16522/j.cnki.cjph.2018.12.013
安神补心制剂
药 品 生 产 微生物检查项目和限值
微生物学质量分析
霉
external
原 人 微生物限度
internal 污染菌的分离、
生 water vapor 菌
water vapor 控
料 员 slow 细
包 产 检查结果分析 鉴定与分析 和
与 与 菌 制
装 环 酵
辅 设 数 菌
境 fast 母
料external 备 slow
water vapor 菌
Drug product exchanges数sorbed water
with headspace water vapor.
瓶内水汽 瓶外水汽
慢过程
快
过
程
慢过程
瓶外水汽
药品吸附的水分可以与瓶内
上部空间的水汽进行交换。
药品包装内外水汽迁移示意图
·药学管理与信息·
1716 美国医疗支付药品福利管理模式的研究·····················熊佳美,金 晶,杨 悦,董江萍*
DOI:10.16522/j.cnki.cjph.2018.12.015
s
P&T每年审查专论为VAC VAC 通过参数进行分析
TAC审查可获取证据为
ERH(%)
p 确定临床参数 为 P&T推荐处方集(对
水活度P&T创建专论
=p = (进一步审查确定药品纳
(药品初审)
0 100 可选药品进行价值评
入、可选、排除) 估)
P&T 审查 VAC推荐
制定最终处方集
(即医保目录)
处方集的制定流程
② 药剂师上传处方至 PBM 系统
1722 药学评价、生物等效性评价、医院药事评价三位一体的仿制药一致性评价方法················
····················································································董双涛,尹 囡,马 郑*
DOI:10.16522/j.cnki.cjph.2018.12.016
杂质对比研究 大数据分析
数据库
药学一致 药效一致
反馈
质量一致
医院采购
1726 长三角地区医疗器械产业创新系统要素配置效率动态研究·······················茅宁莹,马丹丹
DOI:10.16522/j.cnki.cjph.2018.12.017
pharmaceutical hospital pharmacy service bioequivalence
evaluation platform assessment
determination of reference
preparation
创新活动间接主体
diversity 创新活动直接主体 authority
投资机构 生产研发企业
dissolution study
行业协会 long-periodic
政府 high-cost(labour, resources, 创新活动间接主体
raw material, ingredient, 研发机构
中介机构 time) 投资机构
高校
prescription, technique objective 行业协会 政
医院
comparative study on 中介机构
impurities large data analysis
医院
对医疗器械产业创新系统中创新资源投入产出效率进行分析,
发现我国长三角地区各省市之间、系统各主体间的创新效率均存在不同。
data
1733 美国干细胞产业发展政策与监管及对我国的启示··········陈 云,邹宜諠,邵 蓉,周 斌*
DOI:10.16522/j.cnki.cjph.2018.12.018
consistent pharmaceutical
clinical consistent pharmacodynamics
feedback
《中国医药工业杂志》向审稿专家致谢(1693)
Based on the analysis of the input-output efficiency of innovation resources in the medical device industry innovation
system, it is found that the innovation efficiency is different between regions and actors in the Yangtze river delta.
s
min θ ,λθ
∑u y r rj
hj = r =1
( j = 1,2...n) n
m
∑v x i ij
∑x λ
j =1
ij j − θxij ≤0, (i = 1, 2...m)
i =1
n
∑y
j =1
rj λ j ≥ yrj , (r = 1, 2...s)
λ j ≥0, ( j = 1, 2...n)
CONTENTS 粒径
知识空间
Founded in 1970, Monthly
Volume 49, Number 12
Chinese Journal of Pharmaceuticals 多分散性
关键物料比例
December 10, 2018
处方因素 设计空间
包封率
安全性
Perspectives & Review 有效性 ζ电位
工艺因素
1644 Inhalable Nanocarrier-based Drug Delivery Systems for Lung Cancer Therapy························
················································································JIN Y Q, QIU Y, CAO K, HE F*
DOI:10.16522/j.cnki.cjph.2018.12.002
liposomes
超声时间
polymeric nanocarriers 超声振幅
solid lipid超声强度
nanoparticles
孵化
inhalable nanocarrier-based materials
drug delivery system for lung lipid nanocarriers 聚合时间
nanostructured lipid carriers
cancer聚合
therapy 聚合温度
聚合转速
lipid nanocapsules
hybrid lipid-polymer
nanoparticles 水合时间
LHRH receptors
水合温度
水合
folate挥发时间
receptors
挥发温度
溶剂挥发 actively-targeted inhalable cancer cell surface 挥发转速
transferrin receptors
nanoparticles targeting
加热时间
加热 加热温度
epidermal growth factor receptors
包载体积
tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)
包载
tumor endothelium targeting iRGD α v integrins tumor-
homing peptide
Paper
脂质体
construction 脂质纳米囊
脂质聚合物杂化纳米粒
high doxorubicin strain plasmids
LHRH 受体
key genes
conjugation 叶酸受体
genome
ΔdnmV 主动靶向吸入纳米粒 attB site
肿瘤细胞表面靶向
转铁蛋白受体
site-specific scale-up in
表皮生长因子受体
translation integration in
genome
fermenter
肿瘤坏死因子相关凋亡
诱导配体(TRAIL)
O OH
肿瘤血管内皮靶向 O
α v 整合素肿瘤归巢肽
C H OH
OH 2
OH (iRGD)
O biosynthetic pathway
HO
HO
of epirubicin OH O OH O
OH
H3 C O
OH HO
starch or its H2 N
阿霉素高产菌株 质粒构建
关键基因
接合转移
CH3 CH 3
O O O O
L-DET, Ti(O iPr) 4 , DIPEA, toluene CH3 NaOH (a.q) CH 3
O N O N
hydroperoxide, bis(1-methylethyl)phenyl S CH 3CN
S
N N N N
H Na
Dexrabeprazole Sodium
This optimized process has mild reaction conditions and simple operation, and it has been
tested in pilot scale with a totle yield of 83.0%, a purity of 99.9%, and a chiral purity of 99.9%.
DOI:10.16522/j.cnki.cjph.2018.12.005
CH 3 SOCl2 CH 3 N
H CH 3
HCl HCl N
DCM O O
OH Cl NaOH, HO2O / 丙酮 S CH3
N O N O N
H H NH
SOCl2/CH3OH CH3 O CHO HNH HCl
OH O
NH2 NH 2 HCl CH 3CN / i-PrOH O
N N
H HCH 3 NH
CH 3 O
O O O O
CH3 NaOH (a.q) CH 3
L-DET, Ti(O iPr) 4 , DIPEA
O N O N
过氧化氢二异丙苯 , 甲苯 S CH3CN
S
N N
CH3N N
CH
H Na3
O O O Cl O N
Cl H 右旋雷贝拉唑钠
H
Cl CH3NH 2
N O N O
Et 3N, DCM
EtOH
O
改进后的工艺反应条件温和、操作简便,总收率 O
NH 手性纯度 99.9%, 已经过中试验证。
83.0%, 纯度 99.9%, NH
O O
tadalafil
The improved process has mild reaction conditions and simple operation, the purity of
the product is 99.9% with a total yield of 79%, and it has been produced in kilogram scale.
CH
2 盐酸盐 3
O F OH
3 CH3 O
O O NO FCl O N
N
NH2OH·HCl, 1) KOH, toluene / H 2O
Cl Et 3N H H CH 3 F
Cl
CH3NH 2
N O O N O O
HN Et 2) HCl O
3N, DCM
EtOH/H 2O
F HN
L-DET, Ti(O i
OF Pr) 4 , DIPEA, 甲苯
EtOH
HN CH 3 HCl NaOH (a.q)
HCl NH
O ON
NH
intermediate of risperidone
H 3C
O
CH3 S O CH 3CN
The yield was increased to 97% by O OH N他达拉非 N N
H3Ctime to 12 h. CH3
prolonging the reaction H
6
改进后的工艺反应条件温和、操作简便,产品纯度 99.9%,总收率 79%,已实现公斤级生产。
O F OH O
N F N
NH2OH·HCl, Et3N 1) KOH, toluene / H 2O F
1673 Synthesis of the Key Intermediate of Isavuconazonium Sulfate···········································
···································································CHEN H, YANG S, YAO K, LI J Q, LIU Y*
DOI:10.16522/j.cnki.cjph.2018.12.007
O O H 3C O Cl N
CH3 OH 1) Cl O
1) (COCl)2 BH 3 O CH3 , NaHCO3,丙酮 O Boc
OH
OH O CH
O3
N N
CH3 体内 药-时曲线下面积 O O N
2) t-BuOK Boc O O HCl
3C CH 3
N Cl N O
NHMe Cl H 达峰时间 Cl
(R)-carbonyl reductase
2) H C N OH , EDCI, DMAP
3) 甲胺 6 3
最大血药浓度
药代动力学
F
硫酸艾沙康唑鎓关键中间体
F
NAD+ intermediate of nepirolol
NADH
用碳酸氢钠代替二异丙胺在丙酮中反应,反应完全,总收率 64.2%。
微针辅助处理皮肤
gluconic acid glucose
glucose dehydrogenase
不预处理皮肤
盐酸雷莫司琼贴片 稳态渗透速率 离体
48 h累积渗透量
The key intermediate of nepirolol was synthesized in the presence of glucose dehydrogenase coupled
and a chiral 时滞
with (R)-carbonyl reductase, with a yield of 91%, a purity of 98.3%,皮肤渗透 HPLC purity of 99.6%.
O OH
250 O Cl (R)- 羰基还原酶 O Cl
200
F R² = 0.994 5 F
Q/μg·cm-2
150 +
(R)-CLK NADH NAD (R,R)-CLA
100 R² = 0.995 6
葡萄糖酸 葡萄糖
50
葡萄糖脱氢酶
0 10 20 30 40 50 60
灭菌效果检验 培养14 d 内样品管培养
相转化微针贴片 环氧乙烷灭菌
基均澄清,无菌生长。
nt
0
ata
-2
ern
-4
sup
20
0 2.5 5 7.5 10 12.5 15 17.5 20
t/min
15
mAU 1
12
c/ng .ml - 1
10 10
8
6
5 4
2
0
-2
0 2 4 6 8 10 12 -4
t/h
common tablets; sustained-release tablets Agilent0LC -MS-MS
2.5 5 7.5 10 12.5 15 17.5 20
t/min
O CH 0
上清
3 -1 0 1 23 4 5 6
20
t/min
tenofovir disoproxil fumarate genotoxic impurity detection
15
c/ng .ml - 1
10
COOH ×10 3
HOOC 1.4
H2N CH 3 Br
5 O 1.2 CH3
GC -MS/MS
N O 1
N O O CH 3
O 0.8
N0 P 0.6
N O2 4
O 6 8 10 12
Ot/h CH3 0.4
普通片; 缓释片 0.2
安捷伦液质联用仪
CH 3 O O CH 3 0
-1 0 1 2 3 4 5 6
t/min
1705 Microbial Limit Test and Microorganism Identification of Anshenbuxin Preparations·················
·································································LI F, FENG Z, LIU D L, LIU H, YANG M C*
DOI:10.16522/j.cnki.cjph.2018.12.013
microbiological quality
pharmaceutical manufacturing analysis of Anshenbuxin items and limit of microbial test
preparation
isolation,
industrial environment
microorganisms
identification and
raw materials and
specified
analysis of bacteria
packaging
ingredients
count
1710 Water Activity Measurement and Its Application in Pharmaceutical Industry··················NIE S Y
DOI:10.16522/j.cnki.cjph.2018.12.014
安神补心制剂
药 品 生 产 微生物检查项目和限值
微生物学质量分析
internal external
water vapor slow water vapor
霉
原 人 微生物限度
fast 污染菌的分离、
external 生 菌 控
料 员 slow 细
water 包 产
与 vapor
检查结果分析 鉴定与分析 和 制
与 菌
装 环 Drug product 酵
辅 设 数 exchanges sorbed water
菌
境 母
料 备 with headspace water vapor.
菌
数
Humidity Migration in a Bottle
p ERH(%)
水活度 = p =
100 0
仅考虑临床(不考虑经济) 临床和经济
dissolution study
long-periodic high-cost(labour, resources,
raw material, ingredient,
time)
prescription, technique objective
comparative study on
impurities large data analysis
data
创新活动间接主体 创新活动直接主体
投资机构 生产研发企业
政府
行业协会 consistent pharmaceutical 创新活动间接主体 创新活
研发机构
中介机构 clinical consistent pharmacodynamics 投资机构
高校
feedback 生产
医院 行业协会 政府
研
中介机构
consistent quality 医院
对医疗器械产业创新系统中创新资源投入产出效率进行分析,
发现我国长三角地区各省市之间、系统各主体间的创新效率均存在不同。
hospital procurement
1726 Dynamic Study on the Allocation Efficiency of Medical Device Industry Innovation System in
Yangtze River Delta Region······························································MAO N Y, MA D D
DOI:10.16522/j.cnki.cjph.2018.12.017
Based on the analysis of the input-output efficiency of innovation resources in the medical device industry innovation
system, it is found that the innovation efficiency is different between regions and actors in the Yangtze river delta.
1733 The Research and Enlightenment about Development Policy and Regulation of American Stem
Cell Industry·······················································CHEN
s Y, ZOU Y X, SHAO R, ZHOU B*
min θ ,λθ
∑ ur yrj
DOI:10.16522/j.cnki.cjph.2018.12.018
hj = r =1
( j = 1,2...n) n
m
∑v x i ij
∑x λ
j =1
ij j − θxij ≤0, (i = 1, 2...m)
i =1
n
∑y j =1
rj λ j ≥ yrj , (r = 1, 2...s)
λ j ≥0, ( j = 1, 2...n)
中国医药工业杂志
ZHONGGUO YIYAO GONGYE ZAZHI
(月刊,1970年11月创刊) Monthly (Founded in 1970)
2018年第49卷 第12期 12月10日出版 Vol.49 No.12 December 10, 2018
版权所有 ©All Rights Reserved
名誉主编(HONORARY EDITOR-IN-CHIEF)
桑国卫*(SANG Guowei)
顾问(CONSULTANT)
陈凯先*(CHEN Kaixian) 丁 健*(DING Jian) 侯惠民*(HOU Huimin)
蒋建东(JIANG Jiandong) 孔德云(KONG Deyun) 李绍顺(LI Shaoshun)
沈竞康(SHEN Jingkang) 王广基*(WANG Guangji) 吴晓明(WU Xiaoming)
杨胜利*(YANG Shengli) 朱宝泉(ZHU Baoquan)
主任编委(EDITOR-IN-CHIEF)
陈芬儿*(CHEN Fener)
副主任编委(ASSOCIATE EDITOR-IN-CHIEF)(△常务副主任编委)
白 骅(BAI Hua) 陈 兵(CHEN Bing) 陈代杰△(CHEN Daijie)
陈桂良(CHEN Guiliang) 胡文浩(HU Wenhao) 李明华(LI Minghua)
唐 岳(TANG Yue) 王 浩△(WANG Hao) 王军志(WANG Junzhi)
魏宝康(WEI Baokang) 杨 超(YANG Chao) 张贵民(ZHANG Guimin)
张 霁(ZHANG Ji) 张万斌(ZHANG Wanbin) 张绪穆(ZHANG Xumu)
周 斌(ZHOU Bin) 周伟澄△(ZHOU Weicheng)
朱建伟(ZHU Jianwei)
编委(MEMBER OF THE EDITORIAL BOARD)
蔡正艳(CAI Zhengyan) 陈少欣(CHEN Shaoxin) 程卯生(CHENG Maosheng)
邓卫平(DENG Weiping) 丁锦希(DING Jinxi) 董树沛(DONG Shupei)
范代娣(FAN Daidi) 方 浩(FANG Hao) 冯 军(FENG Jun)
傅 磊(FU Lei) 甘 勇(GAN Yong) 干荣富(GAN Rongfu)
郭 文(GUO Wen) 何 菱(HE Ling) 何严萍(HE Yanping)
胡海峰(HU Haifeng) 胡又佳(HU Youjia) 黄志红(HUANG Zhihong)
李范珠(LI Fanzhu) 李建其(LI Jianqi) 刘玲玲(LIU Lingling)
刘新泳(LIU Xinyong) 刘 忠(LIU Zhong) 龙亚秋(LONG Yaqiu)
陆伟根(LU Weigen) 陆伟跃(LU Weiyue) 罗国强(LUO Guoqiang)
罗一斌(LUO Yibin) 吕 扬(LÜ Yang) 马 璟(MA Jing)
潘卫三(PAN Weisan) 朴虎日(PIAO Huri) 邵 蓉(SHAO Rong)
宋秋玲(SONG Qiuling) 苏为科(SU Weike) 孙飘扬(SUN Piaoyang)
孙小强(SUN Xiaoqiang) 孙 逊(复旦大学)(SUN Xun) 孙 逊(四川大学)(SUN Xun)
陶 涛(TAO Tao) 涂 涛(TU Tao) 屠永锐(TU Yongrui)
王建新(WANG Jianxin) 王 健(WANG Jian) 王 旻(WANG Min)
王全瑞(WANG Quanrui) 王善春(WANG Shanchun) 王 彦(WANG Yan)
王玉成(WANG Yucheng) 吴 彤(WU Tong) 吴 伟(WU Wei)
吴 勇(WU Yong) 吴勇琪(WU Yongqi) 杨立荣(YANG Lirong)
杨 明(YANG Ming) 杨苏蓓(YANG Subei) 杨玉社(YANG Yushe)
殷 明(YIN Ming) 尤启冬(YOU Qidong) 张福利(ZHANG Fuli)
张启明(ZHANG Qiming) 张庆文(ZHANG Qingwen) 张卫东(ZHANG Weidong)
张英俊(ZHANG Yingjun) 张志荣(ZHANG Zhirong) 赵临襄(ZHAO Linxiang)
赵文杰(ZHAO Wenjie) 郑起平(ZHENG Qiping) 钟大放(ZHONG Dafang)
钟为慧(ZHONG Weihui) 周虎臣(ZHOU Huchen) 周建平(ZHOU Jianping)
*院士
《中国医药工业杂志》编辑部成员(EDITORIAL STAFF)
总编辑(Managing Editor):周伟澄(ZHOU Weicheng)
副总编辑(Associate Managing Editor):黄志红(HUANG Zhihong),刘玲玲(LIU Lingling)
责任编辑(Editor):刘玲玲(LIU Lingling)(兼),王 盈(WANG Ying),郭琳琳(GUO Linlin),马建芳(MA Jianfang)
美术编辑(Art Editor):沈建成(SHEN Jiancheng),陆燕玲(LU Yanling),钱苗苗(QIAN Miaomiao)
编辑助理(Editorial Assistant):韦旭华(WEI Xuhua)
广告、发行负责(Advertisement Manager):陶旭辉(TAO Xuhui),欧阳怡(OUYANG Yi)
中国医药工业杂志 Chinese Journal of Pharmaceuticals 2018, 49(12) ·1673·
硫酸艾沙康唑鎓关键中间体的合成
陈 华1,2,杨 森3,姚 凯1,2,李建其1,2,刘 育1,2*
(1. 中国医药工业研究总院 上海医药工业研究院 化学制药新技术中心,上海 201203;
2. 上海药物合成工艺过程工程技术研究中心,上海 201203;3. 中国人民武装警察部队 北京市总队保障部卫生处,北京 100027)
褐色固体 3(1.16 kg,103.6% ),直接用于下步反应。 乙酸乙酯 (750 ml),用水 (250 ml×2) 洗涤,用无
用碳酸氢钠代替二异丙胺在丙酮中反应,反应完全,总收率 64.2%。
2- 氯烟酸叔丁酯 (4) 水硫酸钠干燥,过滤,滤液减压浓缩得黄色液体
将上述所得化合物 3 加至无水 THF(10 L) 中, 5(460.0 g,94.2% ),纯度 90.23% (HPLC 方法同
降温至 0 ℃,缓慢加入叔丁醇钾 (1.16 kg,10.3 mol), 4),直接用于下步反应。取少量粗品经柱色谱纯化
控温 0 ~ 10 ℃,1 h 加完。加毕,于常温搅拌反应 [ 洗脱剂 :DCM ∶甲醇 ( 10 ∶ 1) ] 进行结构鉴定。
1
2 h。减压蒸除溶剂后,加入乙酸乙酯 (7.5 L) 稀释, H NMR(400 MHz, CDCl3)δ: 8.30(dd, J=4.7、1.8 Hz,
O O O H 3C O H 3C
CH3 H 3C CH 3
OH (COCl)2 Cl t-BuOK O CH3 NH2 O CH 3
N Cl DCM N Cl THF N Cl N NHMe
2 3 4 5
H3C Cl
Cl CH3
O Cl Boc O O O
7 N 8
BH3 OH Cl O CH3 O O H3C OH
N N
CH 3 H 3C
THF N N NaHCO3, 丙酮 N N EDCI / DMAP
H CH 3 H 3C O
N
OH
6 Boc O
1
图 1 1 的合成路线
Fig.1 Synthetic Route of 1
中国医药工业杂志 Chinese Journal of Pharmaceuticals 2018, 49(12) ·1675·
1H), 8.07(ddd, J=7.6、4.9、2.2 Hz, 1H), 6.51(dd, 甲胺基吡啶 (DMAP,15.0 g,122.0 mmol),常温
J=7.7、4.8 Hz, 1H), 3.07(d, J=4.9 Hz, 3H), 1.64(s, 搅拌反应 1 h,反应液由白色变为浅黄色。过滤,
1H), 1.59(s, 9H)。 滤液减压浓缩。向浓缩物中加入 DCM(250 ml),用
2- 甲胺基 -3- 吡啶甲醇 (6) 0.3 mol/L 盐酸 (1.0 L×2) 洗涤,再依次用水 (1.0 L)
将化合物 5( 555.0 g,2.65 mol) 加至 1 mol/L 和 饱 和 氯 化 钠 溶 液 ( 1.0 L) 洗, 减 压 浓 缩 有 机
硼烷四氢呋喃溶液 (5.34 L,5.30 mol) 中,加热至 相。浓缩物经柱色谱 [ 洗脱剂 :DCM ∶乙酸乙酯
70 ℃回流反应 6 h。置冰水浴中冷却,缓慢加入甲 (20 ∶ 1)] 纯化得淡黄色液体 1(118.0 g,78.6% ),
醇 ( 850 ml) 淬灭反应。加毕,升温至 60 ℃回流 纯 度 98.2 % ( HPLC 条 件 同 4)。ESI-MS( m/z) :
1 h。减压蒸除溶剂,依次加入 DCM( 5 L) 和饱和 316[ M+H- 100] + ;1H NMR( 400 MHz, CDCl 3) δ :
氯化钠溶液 (100 ml),搅拌,分液,弃水层。有机 8.47(s, 1H), 7.83(s, 1H), 7.30(s, 1H), 6.58(s, 1H),
层用无水硫酸钠干燥,过滤,滤液减压浓缩。浓缩 5.21(s, 1H), 5.15(s, 1H), 4.05(s, 1H), 3.96(s, 1H),
物中加入甲苯 (1.0 L),加热至 60 ℃回流 30 min 后, 3.37(d, J=12.1 Hz, 3H), 2.93(s, 3H), 2.05(s, 1H),
冷却析晶。过滤,得白色固体 6(315.0 g,85.6% ), 1.89(s, 1H), 1.57(d, J=4.6 Hz, 1H), 1.45(d, J=12.6 Hz,
纯度 97.04% (HPLC 方法同 4)。mp 103.3 ~ 103.8 ℃ 5H), 1.38(s, 4H)。
1
( 文献 [3]
:104 ℃ )。 H NMR(400 MHz, CDCl3)δ:
8.12(dd, J=5.1、1.7 Hz, 1H), 7.24(dd, J=7.1、1.7 Hz, 参考文献:
1H), 6.52(dd, J=7.1、
5.1 Hz, 1H), 5.35(s, 1H), 4.61(s, [1] US Food and Drug Administration.FDA approves new
2H), 3.04(d, J=4.9 Hz, 3H), 2.05(s, 1H)。 antifungal drug Cresemba [EB/OL].http://www.fda. gov/
newsevents/newrooms/pressannouncements/ucm437106.htm,
N- 甲基 -N-[3-[[(N- 叔丁氧羰基 -N- 甲胺基 )-
2015-03-06/2015-07-28.
乙酰氧基 ] 甲基 ] 吡啶 -2- 基 ] 氨基甲酸 (1- 氯乙基 )-
[2] 顾卫青, 朱 江, 董先红.广谱唑类抗真菌新药艾沙康唑
酯 (1)
[J].中国药师, 2016, 19(1): 166-168.
将 化 合 物 6( 50.0 g,362.0 mmol) 加 至 丙 酮 [3] F U K U D A H , H AYA S E T, M I Z U G U C H I E , e t a l.
( 500 ml) 中,搅拌溶解,加入碳酸氢钠 ( 50.0 g, N-Substituted carbamoyloxyalkyl-azolium derivatives: US,
595.0 mmol),氮气保护。常温下缓慢滴加 7( 萨恩 6812238B2 [P].2004-11-02.
化学科技有限公司,98%,60.0 g,419.5 mmol), [4] TAKABE F, HIRANO Y, FUNYU A, et al.Ring-fused
30 min 内加完。加毕,常温反应 1 h。向上述反应 2-pyridone derivatives and herbicides: US, 8334236 [P].
用硼烷代替四氢铝锂进行还原反应,安全高效。
N
H 3C
O O H 3C O Cl N
CH3 OH 1) Cl O
1) (COCl)2 BH 3 O CH3 , NaHCO3,丙酮 O Boc
OH O CH3 CH3 O
O N
2) t-BuOK N N Boc O H 3C
H Cl CH 3
N Cl N NHMe
2) H C N OH , EDCI, DMAP
3) 甲胺 6 3
硫酸艾沙康唑鎓关键中间体
用碳酸氢钠代替二异丙胺在丙酮中反应,反应完全,总收率 64.2%。
O O O H 3C O H 3C
CH3 H 3C CH 3
OH (COCl)2 Cl t-BuOK O CH3 NH2 O CH 3
N Cl DCM N Cl THF N Cl N NHMe
2 3 4 5
H3C Cl
Cl CH3
O Cl Boc O O O
7 N 8
BH3 OH Cl O CH3 O O H3C OH
N N
CH 3 H 3C
THF N N NaHCO3, 丙酮 N N EDCI / DMAP
H CH 3 H C O